Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -156,730 | -109,559 | -68,174 | -30,471 | -107,431 |
| Depreciation Amortization | 126 | N/A | 54 | 26 | 65 |
| Accounts receivable | -11,633 | -7,918 | -387 | -210 | -596 |
| Accounts payable and accrued liabilities | 16,430 | 1,383 | 1,810 | 675 | 1,251 |
| Other Working Capital | 15,142 | 13,104 | 13,346 | 4,525 | 4,566 |
| Other Operating Activity | 30,553 | 29,834 | 12,090 | 4,241 | 18,818 |
| Operating Cash Flow | $-106,112 | $-73,156 | $-41,261 | $-21,214 | $-83,327 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -254 | -136 | -62 | -18 | -210 |
| Investing Cash Flow | $-254 | $-136 | $-62 | $-18 | $-210 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 200,000 | 200,000 | 200,000 | N/A | N/A |
| Common Stock Issued | N/A | N/A | N/A | N/A | 386,442 |
| Other Financing Activity | 129 | 129 | 129 | 91 | -3,330 |
| Financing Cash Flow | $200,129 | $200,129 | $200,129 | $91 | $383,112 |
| Exchange Rate Effect | -92 | 20 | N/A | N/A | N/A |
| Beginning Cash Position | 400,146 | 400,146 | 400,146 | 400,146 | 100,571 |
| End Cash Position | 493,817 | 527,003 | 558,952 | 379,005 | 400,146 |
| Net Cash Flow | $93,671 | $126,857 | $158,806 | $-21,141 | $299,575 |
| Free Cash Flow | |||||
| Operating Cash Flow | -106,112 | -73,156 | -41,261 | -21,214 | -83,327 |
| Capital Expenditure | -254 | -136 | -62 | -18 | -210 |
| Free Cash Flow | -106,366 | -73,292 | -41,323 | -21,232 | -83,537 |